WALD - Bragar Eagel & Squire P.C. Is Investigating Waldencast Chemours Trupanion and Renovaro and Encourages Investors to Contact the Firm | Benzinga
NEW YORK, March 04, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Waldencast Plc (NASDAQ:WALD), The Chemours Company (NYSE:CC), Trupanion Inc. (NASDAQ:TRUP), and Renovaro Biosciences Inc. (NASDAQ:RENB). Our investigations concern whether these companies have violated the federal securities laws and/or engaged in other unlawful business practices. Additional information about each case can be found at the link provided.
Waldencast Plc (NASDAQ:WALD)
On April 25, 2023, Waldencast announced that it will be unable to file its 2022 annual report on time and will be postponing its fiscal year 2022 and fourth quarter earnings call due to an ongoing review of the Company's year-end 2022 financial statements. Specifically, the Company is conducting an analysis regarding certain accounting issues in connection with the sale of certain Obagi products for the Vietnam market.
On this news, the price of Waldencast shares declined by $0.57 per share, or approximately 6.20%, from $9.20 per ...